Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma
Martini D, Jansen C, Harik L, Evans S, Olsen T, Master V, Kissick H, Bilen M. Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma. Frontiers In Oncology 2021, 11: 793808. PMID: 34976834, PMCID: PMC8716393, DOI: 10.3389/fonc.2021.793808.Peer-Reviewed Original ResearchCD8+ T cellsResponse to treatmentT cellsLymphovascular invasionTranslocation-associated renal cell carcinomaFoci of lymphovascular invasionBiomarker of response to treatmentRadiographic response to treatmentFirst-line treatment optionFavorable response to treatmentIntratumoral immune infiltrationImmune checkpoint inhibitorsResponse to nivolumabRenal cell carcinomaPrimary tumor samplesYear old femalePresence of lymphocytesCheckpoint inhibitorsProgression-freeRare malignancyCell carcinomaPredictive biomarkersImmune infiltrationAggressive malignancyTreatment optionsAbstract PO-041: An immunologic niche of antigen presenting cells and stem-like CD8+ T-cells is present in non-small cell lung cancer brain metastases
Jansen C, del Balzo L, Prabhu R, Logan S, Chappa P, Patel K, Wilkinson S, Lake R, Shu H, Zhong J, Dhere V, Olson J, Sowalsky A, Khan M, Kissick H, Buchwald Z. Abstract PO-041: An immunologic niche of antigen presenting cells and stem-like CD8+ T-cells is present in non-small cell lung cancer brain metastases. Clinical Cancer Research 2021, 27: po-041-po-041. DOI: 10.1158/1557-3265.radsci21-po-041.Peer-Reviewed Original ResearchCD8+ T cellsStem-like CD8+ T cellsNon-small cell lung cancer brain metastasisNon-small cell lung cancerAntigen presenting cellsLung cancer brain metastasisStereotactic radiosurgeryBrain metastasesCancer brain metastasesImmune nicheT cellsPresenting cellsMHC-II+TCF-1CD8+ T cell infiltrationImmunological nichePost-operative stereotactic radiosurgeryPre-operative stereotactic radiosurgeryT cell infiltrationCell lung cancerCohort of patientsCheckpoint blockadePD-1Disease recurrenceGenitourinary malignancies